Avidity Partners Management LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $102 Million - $180 Million	-1,231,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $10 Million - $13 Million	91,000 Added 7.98%	1,231,000 $146 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $20.5 Million - $30.6 Million	205,800 Added 22.03%	1,140,000 $157 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $5.11 Million - $7.18 Million	51,700 Added 5.86%	934,200 $130 Million
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $11 Million - $17.6 Million	-167,300 Reduced 15.94%	882,500 $85.7 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $35.8 Million - $51.2 Million	558,000 Added 113.46%	1,049,800 $71.8 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $51.6 Million - $77.8 Million	-792,400 Reduced 61.7%	491,800 $42.2 Million
Q3 2020 Nov 16, 2020	BUY	$59.04 - $77.95 $10.6 Million - $14 Million	179,700 Added 16.27%	1,284,200 $83.5 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $16.4 Million - $41.9 Million	564,500 Added 104.54%	1,104,500 $80.8 Million
Q1 2020 Jun 17, 2020	BUY	$27.51 - $57.29 $14.9 Million - $30.9 Million	540,000 New	540,000 $18.4 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.